Intellia Therapeutics NTLA Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnInvestments.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's net gains (losses) on investments?
- Intellia Therapeutics (NTLA) reported net gains (losses) on investments of -$904K in Q1 2026.
- How has Intellia Therapeutics's net gains (losses) on investments changed year-over-year?
- Intellia Therapeutics's net gains (losses) on investments increased by 57.5% year-over-year, from -$2.13M to -$904K.
- What is the long-term trend for Intellia Therapeutics's net gains (losses) on investments?
- Over 4 years (2021 to 2025), Intellia Therapeutics's net gains (losses) on investments has grown at a -100.0% compound annual growth rate (CAGR), from -$1.33M to $0.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.